TGFB1 and cancer: This study demonstrated the reliability and feasibility of a drug screening strategy based on cancer-host interaction and showed that Pro might be a potential therapeutic agent in the treatment of bone-metastatic PCa by blocking the TGF-β feedback loop in the bone metastasis.